Lasa Supergenerics Limited (LASA) - Total Assets
Based on the latest financial reports, Lasa Supergenerics Limited (LASA) holds total assets worth Rs716.03 Million INR (≈ $7.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lasa Supergenerics Limited - Total Assets Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's total assets have evolved over time, based on quarterly financial data. Also see Lasa Supergenerics Limited market capitalisation for the company's overall valuation and market capitalisation.
Lasa Supergenerics Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Lasa Supergenerics Limited's total assets of Rs716.03 Million consist of 32.0% current assets and 68.0% non-current assets. Review total liabilities of Lasa Supergenerics Limited to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs5.15 Million | 0.3% |
| Accounts Receivable | Rs15.42 Million | 1.5% |
| Inventory | Rs244.97 Million | 24.1% |
| Property, Plant & Equipment | Rs483.42 Million | 47.6% |
| Intangible Assets | Rs198.94 Million | 19.6% |
| Goodwill | Rs110.67 Million | 10.9% |
Asset Composition Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Lasa Supergenerics Limited for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lasa Supergenerics Limited's current assets represent 32.0% of total assets in 2025, a decrease from 34.8% in 2017.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2025, up from 0.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 2.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 47.6% of total assets.
Lasa Supergenerics Limited Competitors by Total Assets
Key competitors of Lasa Supergenerics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Lasa Supergenerics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 0.81 | 1.45 |
| Quick Ratio | 0.52 | 0.39 | 0.98 |
| Cash Ratio | 0.03 | 0.01 | 0.00 |
| Working Capital | Rs-33.76 Million | Rs-91.52 Million | Rs177.41 Million |
Lasa Supergenerics Limited - Advanced Valuation Insights
This section examines the relationship between Lasa Supergenerics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -32.7% |
| Total Assets | Rs1.02 Billion |
| Market Capitalization | $3.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Lasa Supergenerics Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Lasa Supergenerics Limited's assets decreased by 32.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual total assets of Lasa Supergenerics Limited from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.02 Billion ≈ $10.98 Million |
-32.70% |
| 2024-03-31 | Rs1.51 Billion ≈ $16.32 Million |
-7.93% |
| 2023-03-31 | Rs1.64 Billion ≈ $17.72 Million |
-21.66% |
| 2022-03-31 | Rs2.09 Billion ≈ $22.62 Million |
+0.63% |
| 2021-03-31 | Rs2.08 Billion ≈ $22.48 Million |
-10.40% |
| 2020-03-31 | Rs2.32 Billion ≈ $25.09 Million |
-10.25% |
| 2019-03-31 | Rs2.58 Billion ≈ $27.96 Million |
-9.86% |
| 2018-03-31 | Rs2.87 Billion ≈ $31.01 Million |
+25.64% |
| 2017-03-31 | Rs2.28 Billion ≈ $24.68 Million |
-- |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more